Biosergen publishes information document regarding rights issue
Biosergen AB has published an information document concerning its approximately SEK 40 million rights issue. The company's board approved the issue on June 26, with the general meeting confirming it on August 6.
Biosergen AB announced on August 10, 2026, that it has published an information document regarding its planned rights issue of approximately SEK 40 million. The company's Board of Directors resolved to proceed with the rights issue on June 26, 2026, and this decision was subsequently approved by an extraordinary general meeting of shareholders on August 6, 2026.
The information document provides key details for investors concerning the share issue, intended to strengthen the company's financial position. Specifics on the subscription price, terms, and timeline are now available.
Restrictions apply to the release, publication, and distribution of the document. These limitations exclude certain jurisdictions, including the United States, Australia, Canada, and several countries in Asia and Africa.
Further details on the rights issue can be found within the officially published document.